Medpace Holdings (Medpace Holdings) COGS-to-Revenue : 0.70 (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Medpace Holdings COGS-to-Revenue?

Medpace Holdings's Cost of Goods Sold for the three months ended in Mar. 2024 was $356 Mil. Its Revenue for the three months ended in Mar. 2024 was $511 Mil.

Medpace Holdings's COGS to Revenue for the three months ended in Mar. 2024 was 0.70.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Medpace Holdings's Gross Margin % for the three months ended in Mar. 2024 was 30.36%.

Medpace Holdings COGS-to-Revenue Historical Data

The historical data trend for Medpace Holdings's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medpace Holdings COGS-to-Revenue Chart

Medpace Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.71

0.70

0.71

0.70

0.72

Medpace Holdings Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
COGS-to-Revenue	Get a 7-Day Free Trial															0.70	0.73	0.73	0.73	0.70

Medpace Holdings COGS-to-Revenue Calculation

Medpace Holdings's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	1361.337	/	1885.842
	=	0.72

Medpace Holdings's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	355.902	/	511.044
	=	0.70

Medpace Holdings (NAS:MEDP) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Medpace Holdings's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	355.902 / 511.044
	=	30.36 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Medpace Holdings COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Medpace Holdings's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Medpace Holdings (Medpace Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Medpace Holdings Inc (NAS:MEDP) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

MEDP:Mexico 01P:Germany

Address

5375 Medpace Way, Cincinnati, OH, USA, 45227

Website

https://www.medpace.com

Medpace is a late-stage contract research organization, or CRO, that provides full-service drug development and clinical trial services to small and midsized biotechnology, pharmaceutical, and medical device firms. Medpace also offers ancillary services such as bio-analytical laboratory services and imaging capabilities. The company was founded over 30 years ago, and it has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are principally based in the U.S., but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in February 2014, and it exited Medpace in August 2018.

Executives

Susan E Burwig	officer: Exec. VP, Operations	C/O MEDPACE HOLDINGS, INC., 5375 MEDPACE WAY, CINCINNATI OH 45227
August J. Troendle	director, 10 percent owner, officer: CEO	5375 MEDPACE WAY, CINCINNATI OH 45227
Medpace Investors, Llc	10 percent owner	4620 WESLEY AVENUE, CINCINNATI OH 45212
Robert O. Kraft	director	ONE CVS DRIVE, WOONSOCKET RI 02895
Kevin M. Brady	officer: CFO & Treasurer	MEDPACE HOLDINGS, INC., 5375 MEDPACE WAY, CINCINNATI OH 45227
Stephen P Ewald	officer: General Counsel & Corp. Secy.	C/O MEDPACE HOLDINGS,INC., 5375 MEDPACE WAY, CINTINNATI OH 45227
Femida H. Gwadry-sridhar	director	5375 MEDPACE WAY, CINCINNATI OH 45227
Ashley M. Keating	director	5375 MEDPACE WAY, CINCINNATI OH 45227
Davenport Fred B Jr	director
Brian T Carley	director	C/O MEDPACE HOLDINGS, INC., 5375 MEDPACE WAY, CINCINNATI OH 45227
Mccarthy Cornelius P. Iii	director	5375 MEDPACE WAY, CINCINNATI OH 45227
Jesse J Geiger	officer: CFO & COO, Lab Operations	C/O MEDPACE HOLDINGS, INC., 5375 MEDPACE WAY, CINCINNATI OH 45227
Tom C King	director	5375 MEDPACE WAY, CINCINNATI OH 45227
Medpace Limited Partnership	10 percent owner	EAST WING, TRAFALGAR COURT, LES BANQUES, ST. PETER PORT, CHANNEL ISLANDS Y7 GY1 3PP
Cinven Capital Management (v) General Partner Ltd	10 percent owner	EAST WING, TRAFALGAR COURT, LES BANQUES, ST. PETER PORT Y7 GY1 3PP